Please login to the form below
GSK trials shingles vaccine
GlaxoSmithKline has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles
GlaxoSmithKline (GSK) has commenced late-stage clinical trials of its herpes zoster vaccine currently being developed for the prevention of shingles.
The phase III clinical programme will study more than 30,000 patients worldwide and will evaluate the efficacy, safety and immunogenicity of the vaccine.
Norman Begg, chief medical officer of GSK Biologicals said: "The commencement of the phase III programme for our candidate's herpes zoster vaccine is a significant milestone. Shingles is an often debilitating condition for which there are limited treatment and prevention options.
"Progression into late-stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need," he added.
Herpes zoster is commonly known as shingles. It is caused by the varicella-zoster virus (VZV) and occurs in around 3 out of 1,000 people per year in Europe.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- GSK signs deal with Medicago for COVID-19 vaccine
- FDA approves Roche’s Actemra COVID-19 trial
- Regeneron’s COVID-19 antibody cocktail enters phase 3 trial
- Communiqué Awards 2020: Results
- GSK and Clover’s COVID-19 vaccine starts clinical trials
- Porter Novelli wins first Best Use of Data Visualisation Award at Communiqué 2020
- Gilead reports remdesivir cuts risk of death in severe COVID-19 patients
- Intelligence that redefines success
- New data reinforces safety profile of Roche’s Hemlibra
- Tecentriq misses the mark in advanced ovarian cancer
- DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
- We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
- From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
- Multichannel engagement and the need for greater understanding of European markets
- By Laurence Olding and Georgina James...
Quick links
Infographics
